Kane Biotech Inc. (TSXV:KNE)

Kane Biotech Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	0.85	0.9	0.36	0.75	1.1	1.15
Cash & Short-Term Investments	0.85	0.9	0.36	0.75	1.1	1.15
Cash Growth	-47.01%	151.30%	-52.11%	-32.19%	-4.18%	14.40%
Accounts Receivable	0.04	0.01	0.01	0	0.32	0.18
Other Receivables	-	0.02	0.07	0.1	0.74	0.89
Receivables	0.04	0.04	0.09	0.1	1.06	1.07
Inventory	0.48	0.5	0.38	0.25	0.76	0.52
Prepaid Expenses	0.2	0.25	0.21	0.15	-	-
Other Current Assets	-	-	-	2.47	0.17	0.14
Total Current Assets	1.57	1.69	1.03	3.72	3.1	2.88
Property, Plant & Equipment	0.08	0.48	0.93	1.07	1.25	1.44
Other Intangible Assets	0.57	0.57	0.54	0.73	0.83	0.83
Other Long-Term Assets	-	-	-	0.16	0.44	0.86
Total Assets	2.23	2.73	2.49	5.68	5.62	6.13

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1.16	0.69	1.01	0.44	0.6	0.63
Accrued Expenses	-	0.38	0.64	-	-	-
Short-Term Debt	-	-	-	6.63	4.01	2.39
Current Portion of Long-Term Debt	1.3	1.25	0.34	0.34	0.17	-
Current Portion of Leases	-	0.08	0.12	0.11	0.1	0.13
Current Unearned Revenue	-	-	-	0.75	0.21	0.14
Other Current Liabilities	0.1	0.1	0.3	2.62	1.24	1.43
Total Current Liabilities	2.56	2.5	2.41	10.89	6.34	4.72
Long-Term Debt	0.66	0.62	0.96	1.3	1.6	1.12
Long-Term Leases	-	0.36	0.76	0.87	0.98	1.09
Long-Term Unearned Revenue	-	-	-	0.19	0.84	0.78
Other Long-Term Liabilities	-	-	-	0.83	-	-
Total Liabilities	3.22	3.48	4.12	14.09	9.76	7.7

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	28.82	27.97	24.4	23.69	23.13	22.16
Additional Paid-In Capital	8.55	8.41	8.32	7.75	7.44	5.51
Retained Earnings	-38.68	-37.14	-34.42	-42.13	-37.1	-33.21
Comprehensive Income & Other	0.32	0.01	0.07	0.14	-	1.66
Total Common Equity	-0.99	-0.75	-1.63	-10.56	-6.52	-3.89
Minority Interest	-	-	-	2.15	2.38	2.32
Shareholders' Equity	-0.99	-0.75	-1.63	-8.41	-4.14	-1.57
Total Liabilities & Equity	2.23	2.73	2.49	5.68	5.62	6.13

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1.96	2.3	2.18	9.26	6.86	4.72
Net Cash (Debt)	-1.11	-1.4	-1.82	-8.51	-5.76	-3.57
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.01	-0.01	-0.01	-0.07	-0.05	-0.03
Filing Date Shares Outstanding	83.36	181.86	154.77	131.84	124.85	114.83
Total Common Shares Outstanding	83.36	181.6	137.79	131.84	124.83	114.81
Working Capital	-0.99	-0.81	-1.38	-7.17	-3.24	-1.84
Book Value Per Share	-0.01	-0.00	-0.01	-0.08	-0.05	-0.03
Tangible Book Value	-1.57	-1.31	-2.17	-11.29	-7.35	-4.71
Tangible Book Value Per Share	-0.02	-0.01	-0.02	-0.09	-0.06	-0.04
Machinery	-	0.32	0.42	0.4	0.51	0.47

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error